Trial Profile

A phase 1 study of CLD-401 in a basket of solid tumors

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 22 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CLD 401 (Primary)
Indications Head and neck cancer; Non-small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; Proof of concept

Most Recent Events

22 Feb 2026 New trial record
28 Jan 2026 According to a Calidi Biotherapeutics media release, the company plans to file an IND for its first RedTail lead candidate, CLD-401, in Q4 2026 and streamlined dose escalation study with limited number of doses to be tested. Phase I study expected to be conducted in a basket of solid tumors.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com